Apoptotic cells were shown to induce dendritic cell immune tolerance. We applied a proteomic approach to identify molecules that are secreted from apoptotic monocytes, and thus may mediate engulfment and immune suppression. Supernatants of monocytes undergoing apoptosis were collected and compared using SDS-PAGE and differentially expressed proteins were identified using tandem mass-spectrometry. Thrombospondin-1 (TSP-1) and its cleaved 26 kDa heparin binding domain (HBD) were identified. We show that TSP-1 is expressed upon induction of monocyte apoptosis in a caspase-dependent pattern and the HBD is cleaved by chymotrypsin-like serine protease. We further show that CD29, CD36, CD47, CD51, and CD91 simultaneously participate in engulfment induction and generation of an iDC tolerogenic and phagocytic state. We conclude that apoptotic cell TSP-1, and notably its HBD, creates a signalosome in iDCs to improve engulfment and to tolerate engulfed material prior to the interaction with apoptotic cells.
Introduction
In recent years it has become apparent that upon induction of apoptosis, apoptotic cells play an active role in their own engulfment by signaling professional phagocytes and/or antigen presenting cells, without triggering an inflammatory or autoimmune response [1] [2] [3] [4] [5] .
This process seems to play an important role in homeostasis, resolution of inflammation, and peripheral tolerance induction 4,6-8 . Apoptotic cells have been shown to signal the innate immune system in a variety of ways.
"Eat me" signals on apoptotic cells serve as markers for phagocytes to specifically recognize these cells and subsequently ingest them. Such signals can appear on apoptotic cell membranes. Direct signals include alteration in cell surface phospholipid composition 9 , changes in cell surface glycoprotein expression, distinct alterations in cell surface charge 10, 11 , or expression of specific molecules 12 . Alternatively, certain serum or phagocyte-derived proteins can opsonize an apoptotic cell surface and signal phagocytes to engulf the opsonized cells 4, [13] [14] [15] [16] [17] . Viable cells actively express "do not eat me" signals by restriction of phosphatydilserine to the inner leaflet of their membrane, or "stay away" signals using CD31 expression 18 . Recently, attention has been given not only to apoptotic cell membrane changes and phagocyte receptors, but also to the release of a membranederived phospholipid, lysophosphatidylcholine, which acts as a "find me" signal that is important for phagocytic cell recruitment 19 . Most of these mechanisms suggest efficient identification and clearance of cells undergoing apoptosis, with noninflammatory and nonautoimmune consequences.
We decided to further explore whether apoptotic cells can actively express and secrete molecules that have a physiological significance for their own engulfment and for the environmental immune suppression. We examined whether apoptosis-induced immune suppression exists in an autologous primary cell system such as apoptotic monocytes and immature dendritic cells (iDCs). Monocytes can survive in tissues as macrophages for long periods, but a substantial portion of them constantly undergo apoptosis, either in the absence of anti-apoptotic factors, or following infection or activation. Monocyte apoptosis might also have a special role in cross tolerance and presentation 8, 20 and clearance of non-infected dying monocytes should proceed efficiently with immunosuppressive consequences.
In the current study, we hypothesized that apoptotic monocytes express and secrete proteins that have a role in mediating engulfment and immune suppression. We have applied a proteomic approach to identify proteins that are expressed and secreted when monocyte apoptosis is triggered.
We show that, as a part of death preparation, apoptotic monocytes express and secrete thrombospondin-1 (TSP-1), and the cleaved 26 kDa N-terminal heparin binding domain (HBD) of TSP-1, in a caspase-and serine proteases-dependent way. Using inhibitory monoclonal antibodies within a model of iDC-apoptotic cell interactions, we further show that TSP-1 and HBD directly and indirectly mediate both engulfment and immune suppression.
Materials and methods

Media and reagents
The For apoptosis inhibition, broad-spectrum caspase-inhibitor zVAD-fmk (Bachem, Bubendorf, Switzerland) was used. For serine protease inhibition, TPCK was dissolved in methanol, and added in the indicated concentrations to cells at incubation.
Transmission Electron Microscopy
Freshly isolated and apoptotic monocytes were obtained as described above, fixed with 2.5% glutaraldehyde for 2.5 hrs at RT, and then washed and resuspended in PBS x1 (Ca ++ and Mg ++ free). The cells were then sedimented, postfixed in 1% OsO4 and rinsed in cacodylate buffer and dehydrated in an ethanol gradient series. The cells then were 7 treated with propylene-oxide for 20 min. (2 changes) and embedded in an Araldite resin.
Thin sections were prepared with an ultramicrotom and examined at an accelerated voltage of 100KW using the Phillips TEM (CM12) at X 5600 magnification.
Generation of monocyte-derived dendritic cells (DCs) and interaction with apoptotic monocytes
Immature monocyte-derived dendritic cells (iDCs) were generated as described elsewhere 4 . For interaction assays, 8×10 5 apoptotic monocytes were labeled with 5µg/ml DiI, as described 4 , and were offered to 2×10 5 iDCs on day six of culture (4:1 ratio) for 5 hours at 37°C, in 96-well plates, in 300 µl of iDC culture medium. Uptake was read by flow-cytometry (FACScan TM ), as described 4 . Briefly, iDCs were separated from monocytes based on CD1a and CD14 staining. FSC/SSC distribution and DiI acquisition by iDCs were measured. Validation of the results was done using interaction index 21 .
For light-microscopic evaluation (interaction index), serum-withdrawal apoptotic monocytes were added to iDCs at a ratio of 4:1 or 8:1 and incubated for 5 hours. Next, the cells were washed, cytospinned using a Shandon cytospin centrifuge, fixed and stained according to standard cytological procedures. Fluorescence microscopy was performed using the DeltaVision system (Applied Precision Inc., Issaquah WA, US)
attached to an inverted Zeiss Axiovert microscope using a 100x1.4 Plan-APOCHROMAT objective (Zeiss, Oberkochen, Germany). Image processing was performed using Photoshop imaging software (version 8.0, Adobe Systems Inc., Mountain View CA, US).
Stimulation of iDCs.
For DC maturation assays, unlabeled apoptotic monocytes were offered to iDCs for 5 hours as described above, after which 1-10ng/ml LPS (Sigma-Aldrich) was added. The expression of maturation-related membrane molecules CD86, HLA-DR, and CD83 was examined 20 hours later.
CFSE labeling of responder cells for mixed lymphocyte reaction (MLR)
experiments. These experiments were performed as described in Supplementary Methods. 
Proteomic based identification of secreted proteins from cells undergoing apoptosis
III. ESI-MS/MS. Nano-Electrospray ionization tandem mass spectrometry was carried
out at the mass spectrometry facility in the Interdepartmental Unit of Hadassah Medical School at the Hebrew University of Jerusalem. For trypsin digestion, proteins from concentrated medium fractions were separated by SDS-PAGE. The region corresponding to the differential protein was excised and subjected to an in-gel digestion procedure, as previously described by Matsui, et al. 23 . Briefly, the procedure includes washing and drying of gels, reduction and alkylation, rehydration with 10ng/ml trypsin in 25mM ammonium bicarbonate buffer solution, incubation for 12-to-16 hours at 37°C, and peptide extraction. In-gel tryptic digests were further desalted using C18 ZipTips 
Identification of secreted proteins from cells undergoing apoptosis
TSP-1 medium concentrations were determined using TSP-1 EIA assay (Chemicon, Temecula CA, US). IL-12 concentrations were determined using IL-12 ELISA (Diaclone, Besançon, France), according to the instructions provided by the manufacturer. Western blotting was preformed using monoclonal antibodies against TSP-1 (Ab-11, Neomarkers, Fermont CA, US). Protein extracts from 3x10 7 apoptotic monocyte culture media (separated as described above), and from 3x10 7 lysed monocytes, were loaded on a 4-20% gradient SDS-PAGE gel, transferred to a PVDF membrane (Millipore), and blocked using 20% skimmed milk in PBST (PBS × 1, 0.05-0.1% Tween 20). The membrane was incubated with primary antibody for 2 hours at room temperature or overnight at 4 o C, and then washed with PBST and incubated for 30 minutes with 1:10,000 HRP conjugated goat anti-mouse secondary antibody (Amersham Biosciences, Buckinghamshire, England). Proteins were visualized with EZ-ECL detection kit (Biological Industries).
cDNA synthesis and RT-PCR amplifications
Total RNA was isolated by using the EZ-RNA isolation kit (Biological Industries) according to the manufacturer's protocol. Single-stranded cDNA was synthesized from 2µg RNA samples of the apoptotic monocytes using the superscript preamplification system for first-strand cDNA synthesis, according to the manufacturer's instructions.
PCR was performed using 5'-GAGTCTGGCGGAGACAACAGC and 5'-TTCCTGCACAAACAGGGTGAT primers for TSP-1 (Sigma-Aldrich). The primers were optimized using a specific cloned DNA as well as the temperature gradient cycler (BioMetra, Goettingen, Germany). Relative gene expression levels were adjusted based on beta-actin intensity, using 5'-ATGGTGGGAATGGGTCAGAAG 5'-CACGCAGCTCATTGTAGAAGG primers (Sigma-Aldrich).
Inhibition assays iDCs were exposed to inhibiting antibodies and to various TSP-1 receptors or TSP-1 motifs, before the addition of 2µg/ml TSP-1 and/or apoptotic monocytes. Uptake of FITC-labeled latex beads (Sigma-Aldrich), either with or without the addition of exogenous TSP-1, was used as a control for phagocytosis. Various blocking antibodies were used against TSP-1 receptors or TSP-1 at concentrations of 10µg/ml: anti-CD47 (Neomarkers); anti-CD51, anti-CD29 (Chemicon), anti-CD36 (Serotec, Oxford, UK), and antibodies against TSP-1 type I repeats (clone A4.1, Biomeda, Foster City CA, US); and N-terminal domain (Santa Cruz Biotechnology Inc., Santa Cruz CA, US).
TSP-1 binding assays
Viable and apoptotic monocytes and iDCs were washed twice with RPMI, and incubated for 30 minutes on ice with 10 µg/ml TSP-1. Cells were then rewashed, and stained with anti-TSP-1 antibody (Biomeda), by fluorescence-labeled secondary antibody, and with either FITC-labeled Annexin-V or propridium iodide (PI).
Statistics
Statistical comparisons of mean data were performed using one-way analysis of variance (ANOVA) and the Students' t-test with Bonferroni correction for multiple comparisons.
The Students' t-test was also used to compare uptake, and to compare the expression of surface molecules on DCs.
Results
Monocyte serum withdrawal apoptosis yields a homogeneous apoptotic population with minimal level of necrosis
We studied serum withdrawal-, Fas-, and staurosporine-induced apoptosis pathways in peripheral blood monocytes and found that serum withdrawal is the most homogenous and reproducible method for apoptosis induction. This method results in >70% of monocytes at their early apoptotic phase with a minimal proportion of necrotic cells, as evident from the annexin-V and propidium iodide (PI) staining ( Figure 1A ). Since maximal apoptosis and minimal necrosis was observed at 10-12 hours following serum withdrawal, we used these conditions in all the following experiments, unless indicated otherwise. Apoptosis was also validated using transmission electron microscopy ( Figure   1B ).
Phagocytosis of apoptotic monocytes induces immune paralysis in iDCs
Next we wanted to verify that autologous apoptotic monocyte binding or engulfment have an immunosuppressive effect on iDCs. To estimate the ability of iDCs to phagocytose apoptotic monocytes, DiI-stained apoptotic monocytes were offered to iDCs for five hours. DiI acquisition by the iDCs was quantified using flow-cytometry 4,24 and showed a linear correlation to the number of interacting apoptotic monocytes ( Supplementary Figure 1 ). Interaction and internalization were also observed with light microscopy and verified using fluorescent microscopy ( Figure 2A ). Additional validation was performed using the interaction index, and showed an index of 170±108 for 4:1 and 267±143 for 8:1 (p<0.0001) (see Materials and Methods, and Shoshan, et al. 21 ).
Exposure to LPS is widely used as a model for triggering DC maturation, which in turn leads to upregulation of MHC class II and costimulatory molecules. We therefore tested the ability of interacting autologous apoptotic monocytes to inhibit LPS-induced maturation of DCs. iDCs that were pretreated with autologous apoptotic monocytes exhibited immune paralysis in response to LPS (1-10 ng/ml) with a decrease in expression of both cell surface molecules CD86 and MHC-II ( Figure 2B ), as well as in IL-12 production ( Figure 2C ). Further, a morphological appearance that is distinct from that of classical mDCs was observed ( Figure 2D ). Taken together, these findings demonstrate that interaction with apoptotic monocytes has an immunosuppressive effect on iDCs.
Immunosuppression has generally been attributed to apoptotic cell binding or engulfment 2, 4, 25, 26 . However, as the apoptotic culture media by itself mediated immunosuppression (not shown), we were interested to find out whether proteins secreted from apoptotic monocytes mediate such an effect.
Apoptotic monocytes secrete thrombospondin-1 (TSP-1)
The secreted proteome of serum withdrawal apoptotic monocytes, in the absence and presence of the pan-caspase inhibitor zVAD-fmk (see Figure 1 for apoptotic phenotype), were collected and compared by SDS-PAGE and Coomassie staining ( Supplementary   Figure 2A ). Differentially expressed proteins were then further analyzed by mass spectrometry (MS). One of the proteins identified was TSP-1, which was found both in its full length and its cleaved 26 kDa, N-terminal heparin binding domain (HBD, Supplementary Figure 2B ).
TSP-1, a homotrimeric glycoprotein of ~145 kDa/subunit 27 , was first described as a platelet alpha-granule protein that is released upon activation 28 . TSP-1 has been found to mediate numerous cell-matrix and cell-cell activities through a variety of receptors (reviewed in Adams, 2001) , and to act as a mediator of apoptotic cell engulfment 29, 30 . It has been previously suggested that TSP-1 is secreted by macrophages 29 and dendritic cells 31 , as well as by fibroblasts 30 and other cell types 32 . TSP-1 HBD was previously shown to mediate cell-cell adhesion, but despite its recognition as a possible separate biologically active protein, HBD's physiological role has not yet been established 33 . As we separately identified the 228 amino acid N-terminal fragment of TSP-1 (Supplementary Figure 2B) , we hypothesized that the TSP-1 and, specifically, the TSP-1 N-terminal domain are likely candidates for mediating apoptotic monocyte engulfment and DC immunosupression.
We chose conditions that yield a minimal proportion of necrotic cells during our apoptosis induction assays ( Figure 1 ). Thus, we assumed that TSP-1 observed in the apoptotic medium did not leak from the cytosol due to loss of membrane integrity, but was secreted during induced apoptosis. To confirm the correlation between apoptosis progression and TSP-1 secretion, we examined TSP-1 levels in the apoptotic monocyte medium by EIA using a polyclonal TSP-1 Ab. As shown in figure 3A , TSP-1 concentration in apoptotic monocyte culture medium was shown to rise to a maximum level of ~2µg/ml as apoptosis progressed. No TSP-1 was detected in a lysate of viable monocytes.
As both full length and cleaved HBD were identified by MS, we wanted to confirm the secretion of both TSP-1 and HBD by apoptotic monocytes using Western blot analysis.
As shown in figure 3B , Western blot analysis of the apoptotic medium showed both full length TSP-1 and 26 kDa TSP-1 fragments, whereas Western blot of apoptotic cell lysate ( Figure 3C ) showed only the full length protein. Viable monocytes ( Figure 3B and 3C), iDCs, and mDCs (not shown) did not contain or secrete TSP-1 in any significant levels on Western blot.
Monocyte serum withdrawal apoptosis induces de novo TSP-1 synthesis
We examined whether TSP-1 is secreted from readily available pools due to the apoptotic process, or is synthesized de novo upon apoptosis induction. As shown in Figure3A, a gradual increase in supernatant content of TSP-1 correlated with the apoptotic process.
Furthermore, lysates of viable monocytes did not contain TSP-1, indicating that pre-apoptotic cells did not contain cellular TSP-1. We then tested TSP-1 mRNA transcription, as shown in Figure 3D and 3E. TSP-1 mRNA levels rose upon induction of apoptosis, and peaked after 10 hours. Thus, despite being in the process of cell death, apoptotic monocytes actively synthesized mRNA for de novo generation of TSP-1. In contrast, TSP-1 mRNA levels were much lower in viable monocytes.
TSP-1 is expressed in other modes of monocyte apoptosis and in neutrophil apoptosis
In order to examine if TSP-1 is expressed in other modes of monocyte apoptosis, we induced apoptosis using anti-Fas monoclonal antibody or staurosporine. Both anti-Fas and staurosporine induced TSP-1 expression and secretion ( Supplementary Figure 3) . We then set out to examine the specificity of TSP-1 expression and secretion to cell type. We examined TSP-1 levels in the apoptotic neutrophil medium by EIA, and were able to see increasing TSP-1 levels upon apoptosis progression ( Supplementary Figure 3 ) similar to levels detected with apoptotic monocytes. Thus, TSP-1 expression is not confined to apoptotic monocytes, and may represent a more general phenomenon of leukocyte and other cell apoptosis. The 26 kDa fragment was also seen in both other modes of monocyte apoptosis, as well as in neutrophil apoptosis (not shown).
Expression of 26 kDa HBD of TSP-1 is caspase and serine protease-dependent
TSP-1 expression was markedly reduced in the presence of zVAD-fmk, indicating that TSP-1 expression is caspase dependent. However, the cleavage site of HBD does not
show an aspartic acid motif that could indicate caspase involvement in cleavage. Several proteases other than caspases, including serine proteases, have been implicated in various activities during apoptosis [34] [35] [36] . Indeed, the HBD cleavage site suggests involvement of serine proteases, specifically of a chymotrypsin-like protease [37] [38] [39] . To examine the possibility that a chymotrypsin-like protease was involved in generation of the 26 kDa TSP-1 cleavage product, we added the chymotrypsin inhibitor N-p-Tosyl-Lphenylalaninie chloromethyl ketone (TPCK). EIA and Western blot analysis indicated that TPCK inhibited cleavage of the 26 kDa HBD in apoptotic monocytes at 1-10 µM concentrations (Supplementary Figure 4A and 4B) , and was toxic (80% of cells were depleted) at 100 µM. Thus, upon induction of apoptosis, chymotrypsin-like serine protease is activated and cleaves TSP-1, yielding the 26 kDa HBD fragment.
TSP-1 improves engulfment and induces immunosuppression in iDCs
We then set out to examine whether TSP-1 can account for the observed apoptotic cell engulfment, immunosuppression, or both. iDCs were incubated with washed apoptotic monocytes, either with or without the addition of exogenous TSP-1. The TSP-1 concentration chosen was the same level observed following 10 hours of monocyte apoptosis (2µg/ml, see Figure 3A ). Adding TSP-1 to the interacting apoptotic monocytes and iDCs improved iDC uptake of apoptotic monocytes by 60% on average, with a mean fluorescence of 601 in the absence of exogenous TSP-1, and 960 in the presence of TSP-1 ( Figure 4A ). TSP-1 also inhibited DC plasma membrane expression of maturationrelated molecules CD86 and MHC class II ( Figure 4B ) by 47.4% and 38.5% respectively.
IL-12 production was also decreased by 51% (not shown).
TSP-1 extensively binds iDCs, but scarcely binds apoptotic monocytes
TSP-1 was previously suggested to function as a bridging molecule between apoptotic cells and macrophages, thereby increasing apoptotic cell phagocytosis 29 . We therefore hypothesized a similar role for TSP-1 in our model, and examined whether TSP-1 binds both apoptotic monocytes and iDCs. Purified TSP-1 was added to washed apoptotic monocytes and iDCs, and cell surface bound TSP-1 was measured by flow-cytometry using anti-TSP-1 monoclonal antibody directed against the type I repeats (clone A4.1).
Surprisingly, in comparison to binding of viable monocytes, only scant additional binding
to Annexin-V positive monocytes was observed ( Figure 5A ). This mild increase in binding was confined to PI positive cells ( Figure 5B) . In contrast, a three-fold increase in binding of TSP-1 to iDCs was observed ( Figure 5C ).
We concluded that the proposed classical bridging role of TSP-1 as a factor increasing phagocytosis of apoptotic cells may not be the only mechanism responsible for the increase in engulfment that was observed. We then were interested to know whether TSP-1 may mediate its function by directly affecting iDCs and not necessarily during the actual uptake of apoptotic cells ( Figure 6A ).
TSP-1 actions of engulfment and immunosuppression, are mediated even in the absence of apoptotic monocytes
Next, we checked whether TSP-1 alone can account for iDC enhancement of engulfment and the observed tolerogenic profile, or whether apoptotic monocytes must also be present. TSP-1-treated iDCs were incubated with green fluorescent latex beads as bait. As seen in figure 6B , iDC engulfment of the latex beads increased by 35.7 ± 3.5% over control in the presence of TSP-1. Thus, an increased engulfing capacity that is nonspecific to apoptotic cells was observed, possibly due to bridging effect or due to direct effect on iDCs. Furthermore, TSP-1-treated DCs displayed an immunoparalyzed phenotype ( Figure 6C ), even in the absence of apoptotic monocyte engulfment. Adding only TSP-1 to iDCs decreased expression of iDC maturation molecule levels by 38 ± 10.5% (p<0.001) and 39 ± 6% (p<0.001), for MHC-II and CD86 respectively. In order to see whether DC immunoparalization was indeed effective, we conducted MLR experiments in which T cell proliferation was clearly inhibited by 30-50% ( Figure 6D ).
We conclude that TSP-1 increases iDC engulfing capability either by binding to iDCs or by binding to both latex beads and IDCs, and has a direct immunosuppressive effect resulting in generation of tolerogenic DCs, even in the absence of apoptotic cells.
Induction of engulfment and immunosuppression requires cooperation between multiple receptors and is mediated mainly by the heparin-binding domain (HBD)
In order to explore the mechanisms underlying these observations, we sought to elucidate the exact sites for TSP-1 binding that mediate these effects. We focused on known TSP-1 receptors. For this, we carried out inhibition assays by exposing iDCs to inhibiting antibodies directed to several TSP-1 receptors or domains, both in the presence and the absence of apoptotic monocytes. While exposure of iDCs to αCD36 or αCD91 inhibiting antibodies prior to interaction significantly decreased apoptotic monocyte engulfment, exposure to an antibody against the N-terminal domain (HBD) decreased engulfment even further, almost to the basal level of TSP-1 mediated engulfment. In contrast, addition of either anti-β1 integrins, or anti-CD47 had no significant influence on engulfment, and addition of anti-CD51 only slightly inhibited apoptotic monocyte uptake ( Figure 7A ).
As for inhibition of the immunosuppressive effect, addition of anti-N-terminal domain, anti-β1 integrins, and anti-CD36 antibodies had the most striking effect on maturation molecule expression. In most cases there was no significant difference whether apoptotic monocytes were added or not ( Figure 7B and 7C ). There was a similar effect by most inhibiting antibodies to avoid downregulation of DR and CD86 expression by TSP-1, but the impact was more pronounced with antibodies directed against the N-terminal domain of TSP-1.
As CD36 and CD91 may mediate binding or engulfment via a non-TSP-1-dependent mechanism, experiments were also conducted in the absence of TSP-1, and in the presence of anti-CD36 and anti-CD91 inhibitory antibodies. No significant inhibition was found in these conditions (not shown), suggesting that the major inhibitory effect was related to TSP-1.
Thus, TSP-1 has multiple domains that induce phagocytic and tolerogenic states in iDCs.
HBD, interacting with iDCs, is a critical domain in regard to both engulfment and immunosuppression. As shown here, this domain is expressed by apoptotic monocytes and neutrophils, both to mediate their own engulfment, and to negatively signal iDCs.
Discussion
In the current study, we have used an unbiased proteomic approach to identify apoptosisrelated secreted proteins that may participate in engulfment mediation and immune suppression. We were able to identify TSP-1, whose secretion has previously been ascribed mainly to the engulfing cell, as a protein that is synthesized de novo upon apoptosis induction in monocytes.
TSP-1 is a calcium-binding protein that participates in cellular responses to growth factors, cytokines, and injury 32, 40 . It regulates cell proliferation, migration, and apoptosis in a variety of physiological and pathological settings, including wound healing, inflammation, angiogenesis, and neoplasia. TSP-1 binds to a wide variety of integrin and non-integrin cell surface receptors ( Figure 6A ). The binding sites for these receptors on TSP-1 are dispersed throughout the molecule, with most domains binding multiple receptors. In some cases, TSP-1 binds to multiple receptors concurrently, and recent data indicate that there is crosstalk between receptor systems. Thus, TSP-1 may direct the clustering of receptors to specialized membrane domains for adhesion and signal transduction.
Although it has long been appreciated that TSP-1 plays a role in mediating apoptotic cell engulfment, its source was mainly attributed to the engulfing cell and its role was mainly attributed to facilitating phagocytosis as a bridging molecule. We were able to show for the first time that, upon apoptosis, monocytes transcribe and translate TSP-1 de novo, and that TSP-1 has a direct facilitating effect on engulfment and immunosuppression.
How may TSP-1 receptor binding ameliorate apoptotic cell engulfment? Interestingly, TSP-1 was shown to induce Fak-dependent signaling to stimulate focal adhesion disassembly and cell migration. Furthermore, RhoA inactivation is required for this response 41 . RhoA inactivation may occur via mechanisms similar to those described for apoptotic cell engulfment in C elegans 42 with CD91 homology to mammals.
Until now, immunosuppressive characteristics were attributed only to TSP-1 interaction with CD47 31 , which in turn interacts with the C-terminal domain. In the current study, we were able to determine that the N-terminal region, the HBD, serves as a potent ligand for engulfment and immunosuppression. The N-terminus of TSP-1 and TSP-2 has sequence similarity to the pentraxin superfamily, by virtue of its globular structure. The pentraxin family has been associated with apoptotic cell clearance. Furthermore, the heparinbinding domain has been shown to interact with calreticulin and CD91, which are related to apoptotic cell clearance in both mammals 43 and C elegans 44, 45 . Although TSP-1 is not found in C elegans, the HBD motif is found in four proteins in C elegans (InterPro search, http://www.ebi.ac.uk/interpro/). The heparin-binding domain supports cellular adhesion 46, 47 and chemotaxis 48, 49 .
What advantages could a 26 kDa HBD fragment have over the full length TSP-1? It is possible that HBD is cleaved rather late in the apoptotic process, in order to ameliorate the clearance of longstanding apoptotic cells. Another possibility is that HBD has different properties and roles than TSP-1, such as proangiogenic activity that may be important in the context of cellular adaptation to injury 33 . Alternatively, experiments using blocking antibodies suggest that signalosome created by HBD may differ from this of whole TSP-1. For example, Saumet, et al. 50 showed that domains outside the HBD, namely the type III repeats/C-terminal domain, trigger caspase-independent cell death.
Given the findings of this and earlier studies, we would like to propose a mechanism of action involving de novo TSP-1 synthesis by apoptotic monocytes, and secretion of either intact TSP-1 or its cleaved 26 kDa HBD. Upon synthesis or secretion, TSP-1 or the HBD binds mainly to iDCs or engulfing cells. TSP-1 triggers the formation of a signalosome that increases phagocytic capacity and mediates inhibitory signals, resulting in a tolerogenic iDC phenotype, and may form a bridging molecule. Apoptotic cells then bind -either via TSP-1 and its relevant receptors, CD91/Calreticulin (LRP), CD36, and αvβ3 -or via other specific engulfing apoptotic cell receptors such as Mer, CD11b/CD18 (if complement opsonization occurs), αvβ5, or αvβ3. The theoretic phosphatydilserine receptor is another possibility 51, 52 . Most important, this tolerogenic phenotype is effective for T cell suppression ( Figure 6D ) and can be acquired by iDCs, even in the absence of interaction with apoptotic cells, indicating the crucial role that TSP-1, and particularly the 26 kDa heparin-binding domain fragment of TSP-1, play in creation of a tolerizing state.
We were not able to document TSP-1 generation by iDCs at the mRNA or protein level, as suggested by Doyen et al. 31 , but this is another possible mechanism ( Figure 6A ).
The mechanism described here also suggests the formation of multiprotein complexes on This mechanism is not only important in homeostasis, but may also be a major mechanism for turning down inflammation and avoiding autoimmunity. (A) Apoptotic monocytes interacting with iDCs. Two DiI-stained apoptotic monocytes are surrounded by iDC pseudopods, and engulfed apoptotic fragments are seen within the dendritic cell (Fluorescent microscopy, magnification x 100). (B) Apoptotic monocyte engulfment downregulates the expression of maturation-related molecules on DCs. Apoptotic monocytes were offered, or not offered, to iDCs at a ratio of 4:1. Five hours later iDCs were exposed to 5ng/ml LPS. HLA DR-FITC and CD86-FITC expression was measured by flow-cytometry. DR and CD86 are expressed at baseline levels in iDCs (mean fluorescence 918 and 640 respectively), and are upregulated following exposure to LPS (Mean fluorescence of 1256 and 1159 respectively). Upregulation by LPS is inhibited by exposure to apoptotic monocytes for both DR (mean fluorescence of 886, p<0.001) and CD86 (mean fluorescence of 756, p<0.01).Values represent the means ± S.E.M. of three experiments. (C) Apoptotic monocyte engulfment decreases IL-12 p40 production by DCs exposed to LPS. Immature DCs secrete IL-12 in response to LPS. Following interaction with apoptotic cells, downregulation of IL-12 secretion is observed. Data represents the mean ± S.D. of three experiments. (D) Apoptotic monocytes prevent appearance of mature DC morphology in response to LPS. iDCs change morphology, becoming elongated and more "dendritic", as they transform into mDCs in response to LPS. Following interaction with apoptotic cells, iDC morphology is retained despite exposure to LPS. as verified by mass spectrometry. A degraded 26 kDa fragment (thick arrow) is also seen. TSP-1 monomers appear as three bands at ≥ 130 kDa, as verified by massspectrometry (arrows). TSP-1 is seen only in apoptotic monocytes. (C) TSP-1 differentially degraded/glycosilated monomers appear as three bands at ≥130 kDa, and all perform full peptide coverage at mass-spectral analysis (arrows). TSP-1 is evidently seen only in apoptotic monocytes. Protein from 3x10 7 cells, from culture media of viable (0 hours, Figure B ), or apoptotic monocytes (8 and 16 hours, Figure B) , and from whole cell lysed viable (0 hours, Figure C ), or apoptotic monocytes (8 and 16 hours, Figure C) , was loaded and separated by SDS-PAGE, as described in materials and methods. Proteins were transferred to the PVDF membrane and exposed to mouse anti-human triclonal TSP-1 antibody, and then to goat-anti-mouse HRP. ECL results are presented. Viable and apoptotic monocytes and iDCs were washed twice with RPMI, and incubated for 30 minutes on ice with 10 µg/ml TSP-1. Cells were then rewashed, and stained with anti-TSP-1 antibody (Biomeda), by fluorescence-labeled secondary antibody, and with either FITC-labeled Annexin-V or propridium iodide (PI).
(A) TSP-1 scarcely binds apoptotic monocytes. Double staining with anti-TSP-1-PE and Annexin-V-FITC is shown. Only 28% (18/64) of Annexin-V-FITC positive monocytes bounded TSP-1. Numbers indicate percentage of cells included in the respective quadrants. (B) TSP-1 binds late, rather than early to apoptotic monocytes. Double staining with anti-TSP-1-FITC and PI is shown. Almost all monocytes that bind anti-TSP-1, are PI-positive late apoptotic cells. This is true also for the small fraction of PI-positive cells that are included in viable cells. (C) TSP-1 binds extensively to iDCs. TSP-1-bound iDCs had a mean fluorescence of 26, whereas viable and apoptotic monocytes show mean fluorescence of 9.14 and 9.73 respectively (p<0.001). Data shown is representative of three experiments. Isotype control is shown as a gray-filled curve. Less than 5% of iDCs were Annexin-V positive and <1% were PI-positive, excluding binding to iDCs due to apoptosis. Mechanisms of TSP-1 as a bridging molecule. TSP-1 may be expressed by phagocytes (B1) or by apoptotic cells that also can secrete the N-terminal domain (B2). Whether the source is the engulfing cell or the apoptotic cell, TSP-1 or the N-terminal domain serve as a bridge between apoptotic cells and phagocytes (B3). A.C. Alternatively (no bridge), TSP-1 or the N-terminal domain may bind to iDCs and induce ameliorated phagocytosis and immune suppression, even in the absence of attached apoptotic cells. (B) TSP-1 enhances latex bead engulfment by iDCs. Green fluorescent latex beads were offered to iDCs at a 16:1 ratio, in the presence or absence of 2 µg/ml TSP-1. The gray-filled curve represents iDCs that were not exposed to green fluorescent latex beads. 22.6% ± 0.1% of the TSP-1 treated iDCs engulfed at least 1 latex bead, compared to 15.6% ± 1.8% in the absence of TSP-1, indicating ~45% augmentation of phagocytic capacity following TSP-1 exposure (P<0.001). Data is representative of three experiments. (C) TSP-1 inhibits iDC maturation. iDCs were treated with 5 ng/ml LPS in the absence or presence of 1µg/ml TSP-1, or remained untreated. Mean fluorescence decreased from 453 to 283 (38%, p<0.001, representative of three experiments) for DR and from 53 to 21(39%, p<0.001, representative of three experiments), for CD86. The bright-filled curve represents isotype control. (D) TSP-1 inhibits T-cell activation. CFSE labeled T cells were cocultured in different ratios with LPS-treated DCs (left), or DCs that were exposed to TSP1 for 5 hours before LPS treatment (right). Exposure to TSP1 prior LPS treatment inhibited DC-induced T-cell activation by 27% at 2:1 T cell : DC ratio and by 50% at 4:1 T cell : DC ratio. iDCs were exposed to several blocking antibodies directed against various potential TSP-1 receptors, washed, and then offered DiI-stained apoptotic monocytes in the presence of 2 µg/ml TSP-1. (A) TSP-1-dependent apoptotic monocyte engulfment is mainly mediated through the HBD. Striking (90%) inhibition of apoptotic monocyte uptake is seen upon inhibition of binding through the HBD (p<0.0001). Significant uptake inhibition is seen upon inhibition of CD36 (64%, p<0.001), whereas slight uptake inhibition is observed upon neutralizing CD51 (24%, p<0.05). No significant engulfment inhibition is seen when CD47 and β 1-integrin domains (CD29) are inhibited. Inhibition is presented as a percentage of TSP-1-dependent engulfment. Data is a mean ± SEM of three experiments. (B-C) TSP-1 induced maturation inhibition involves multiple domains. Expression of DR (B) and CD86 (C) was indicative of the level of DC maturation. iDCs were treated with inhibiting antibodies as described above, and were then exposed to TSP-1 with or without the addition of apoptotic monocytes. 5 ng/ml LPS was added 5 hours later, and expression of DR and CD86 was examined 20 hours later. As shown, the main effect was achieved by blocking HBD (p<0.0001), but other binding sites, such as CD36, CD29 (β1 integrins), CD51, and CD47, also had important immunosuppressive effects (p<0.0001 for each site). The relative inhibition effects on maturation are expressed as the relative changes in DR and CD86 median fluorescence of DCs, compared to DCs treated with isotype control and exposed to LPS. Data is a mean ± SEM of four experiments.
% of TSP-1 dependent engulfment inhibition
